Interim financial report for the period 1 January 2010 to 30 June 2010
5 August 2010
Novo Nordisk increased operating profit by 19% in the first half of 2010. Sales growth of 14% driven by modern insulins and Victoza®. The guidance for 2010 has been raised; sales growth measured in local currencies is now expected to be 9-10%, and operating profit growth measured in local currencies is now expected to be 12-15%. "The underlying business growth is solid, driven by our portfolio of modern insulins and Victoza®, and we therefore raise our guidance for 2010. We are also very encouraged by the continued progress within our pipeline including both new insulins, liraglutide for obesity and haemostasis projects," says Lars Rebien Sørensen, president and CEO.
Interview on CNBC Europe of Jesper Brandgaard
Interview on CNBC Europe 5th August 2010
View the interviewRSS Feed
The latest Novo Nordisk news are now available through Really Simple Syndication - RSS.
